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TCT-306
Use Of The Novel Sideguard Dedicated Bifurcation Stent; A Real World
Experience
Mamas Mamas, Sanjay Sastry, Karen Palmer, Magdi El-Omar, Doug Fraser, Farzin
Fath-Ordoubadi
Manchester Heart Centre, Manchester, United Kingdom
Background: PCI treatment of bifurcation disease is technically challenging and
associated with both lower procedural success and higher MACE rates than observed
in non-bifurcation lesions. The optimal treatment strategy for bifurcation lesions
remains unclear and dedicated bifurcation stents have been developed to address some
of the challenges associated with bifurcation lesions. The Sideguard stent is a novel
nitinol self-expanding dedicated bifurcation stent that flares proximally at the ostium
of the side branch (SB) thereby achieving full ostial coverage. The aim of this study is
to report clinical utility and outcomes of the Sideguard stent in patients undergoing
treatment to bifurcation coronary lesions in a real world setting in a large tertiary UK
centre.
Methods: Data was prospectively collected from over a 1-year period from March
2010-2011.
Results: Over a 1 year period, 1630 PCI procedures involving 1954 lesion were
performed in our centre of which 315 were bifurcation lesions (16.1%); 246 were
treated with single stent strategy (78.1%) whilst 69 were treated with 2 stent strategy
(21.9%). 40 lesions were treated with the Sideguard dedicated side branch stent in 38
patients. The mean age of the patients was 58.2±12.0 years old (mean±SD) and 35/40
lesions were true bifurcation lesions (87.5%). The sideguard stent was successfully
used in all 38 cases including several that would have been technically difficult using
conventional bifurcation techniques. There were no peri-procedural complications and
MACE event rates were 5.3% at 1 year (TVR at 3 months in 1 patient and MI at 7
months in a second patient).
Conclusion: In one of the largest clinical experiences to date, the Sideguard stent can
be used to treat complex bifurcation lesions in a straight forward manner, with excellent
short and long term clinical outcomes and is not subject to the limitations associated
with conventional bifurcation PCI techniques such as maintenance of access to the SB,
having a guidewire secured in the main vessel throughout the procedure and ability to
fully cover the ostium of the SB.
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Background: No prior study has addressed the impact of clinical presentations on
outcomes in patients with coronary bifurcation lesions. Therefore, we examined the
independent prognostic value of acute coronary syndrome (ACS) in patients with
coronary bifurcation lesions treated with drug-eluting stents (DES).
Methods: We enrolled 1,668 patients, using data from “The COBIS (Coronary
Bifurcation Stenting) registry”. The primary objective was to compare the 2-year
cumulative risk of major adverse cardiac events (MACE) in patients with ACS to those
with stable angina.
Results: Nine hundred sixty nine patients presented with ACS and 699 patients
presented with stable angina. Baseline clinical, angiographic and procedural
characteristics of the 2 groups are listed in Table. Two-year MACEs were 7.3% in
patients with ACS and 5.2% in stable angina patients (p=0.042), mainly driven by
higher TLR rate. However, cardiac death, MI, TLR, and stent thrombosis (ST) were
1.1%, 1.4%, 5.5%, and 0.6% in patients with ACS, respectively, and 0.6%, 1.0%, 3.9%,
and 0.7% in patients with stable angina (for cardiac death, p=0.21; for MI, p=0.36; for
TLR, p=0.08; for ST, p=0.87). ACS had a borderline statistical significance (adjusted
HR 1.49, 95% CI 0.99-2.25, p=0.06) in predicting MACEs. In the ACS patients cohort,
baseline lesion length in side branch (adjusted HR 1.04, 95% CI 1.01-1.07, p=0.022),
paclitaxel-eluting stents in main vessel (adjusted HR 2.02, 95% CI 1.21-3.40, p=0.008),
and final kissing balloon dilatation (adjusted HR 1.88, 95% CI 1.10-3.21, p=0.021)
were independent predictors of MACEs.
Clinical, angiographic, and procedural characteristics
Conclusion: Patients with bifurcation lesions and ACS treated with DESs have a
tendency to increase the risk of MACEs during the 2-year follow-up after intervention
compared to stable angina patients.
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Left Main Bifurcation Stenting: Long Term Followup of Simultaneous Kissing
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Background: Stenting the left main stem (LMS) is accepted. Most lesions involve the
bifurcation. Whilst a single stent strategy is established generally, this is not the case
at the LMS bifurcation. We present the results of simultaneous kissing stenting (SKS)
for this indication.
Methods: A single operator registry. We treated consecutive, unselected patients with
bifurcation LMS disease ± multi-vessel disease with SKS and maximal
revascularisation, from 2004, using drug-eluting stents (DES) and recorded clinical
status at baseline, 30d, and 1 and 2 years
Results: 140 patients completed 1 year follow-up. Mean age was 67 years, 75% were
male, 35% were non-elective, the New York Risk Score estimation of in-hospital
mortality was median 0.6% (range 0.1-64) and EuroSCORE 2.6 (0.9-67). SKS were
deployed successfully in 100% cases and DES in 94.3%. 2.0±0.9 other vessels were
diseased and 1.9±0.8 treated. The 30d mortality was 6% [NY Risk 21(0.6-64)] and all
deaths were in the acute coronary syndromes. The mortality rate at 1 year was 11%
(2% elective), and at 2 years 13%. 8/10 out-of-hospital deaths were attributable to
probable (1) or possible (7) stent thrombosis and 7 were not surgical candidates.
Ischemia-driven TVR was 4% at 1 year, and 6% at 2 years. There was 1 stroke, 1
STEMI and no emergency CABG at 2y
SKS of 1,1,1 LMS bifurcation stenosis
Conclusion: This is the largest registry of patients treated for LMS bifurcation disease
with SKS in the world. This technique is simple, feasible and practical, including
patients in extremis or unsuitable for CABG. Long-term results are excellent, and
dependent upon clinical status
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Background: Second-generation drug-eluting stents for the treatment of coronary
artery disease (CAD) are believed not only to be more effective but also safer. Our aim
was to assess the clinical outcomes after everolimus-eluting stent (EES) implantation
in patients undergoing percutaneous coronary intervention for unprotected left main
CAD.
Methods: All consecutive patients from our single-center prospective registry treated
for unprotected critical left main stem stenosis with EES implantation from October
2006 to June 2010 were analyzed. The study endpoints were all-cause mortality,
myocardial infarction (MI), major adverse cardiac event (MACE), target vessel
revascularization (TVR), target lesion failure (TLF) and target lesion revascularization
(TLR).
Results: A total of 62 patients were included: the mean age was 67.9 ± 11.4 years and
75.8% were male. The median clinical follow-up was 723.5 days (interquartile range
265.8–1073.0 days). 53.2% underwent PCI with Xience V/Xience Prime (Abbott
Vascular, Redwood City, California, USA) and 46.8% with Promus/Promus Element™
(Boston Scientific, Natick, MA, USA). 43.5% of patients had left main stenosis
associated with triple vessel coronary artery disease and the mean left ventricular
ejection fraction was 55.8 ± 8.1%. Regarding the procedure, 21.0% had an intra-aortic
balloon pump inserted prior to intervention and intravascular ultrasound guidance was
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